Editor's Pick: Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial (Nephrology Dialysis Transplantation, 2026)

Welcome to This Week in Nephrology. This week we're covering 10 notable papers spanning the frontier of transplantation and organ access, risk prediction and diagnostics across chronic kidney disease, and the practical business of drug therapy and sh…

This week's papers: 1. Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study. — The Lancet 2026 2. Protocol kidney biopsy in the management of proliferative (class III/IV) lupus nephritis: barking up the wrong tree! — Nephrology Dialysis Transplantation 2026 3. Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial. — Nephrology Dialysis Transplantation 2026 4. Predictive Value of Urine Tubular Biomarkers on Kidney Outcomes: Observations from EMPA-KIDNEY. — Clinical Journal of the American Society of Nephrology 2026 5. Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes. — Nature Reviews Nephrology 2026 6. CKD risk with tegoprazan versus proton pump inhibitors. — Nephrology Dialysis Transplantation 2026 7. Urine Albumin-to-Creatinine Ratio Reveals Kidney Disease Improving Global Outcomes Risk Reclassification in Cardiovascular-Kidney-Metabolic-Era Community Scree… — Kidney360 2026 8. A Randomized Pilot Trial of a Nephrologist Communication Tool for Discussing Conservative Management. — Clinical Journal of the American Society of Nephrology 2026 9. Regional Disparities in Living Donor Kidney Transplantation: An Analysis of Transplant Referral Networks. — American Journal of Transplantation 2026 10. Quantum Dot-Based Fluorescent Lateral Flow Immunoassay Strip for Rapid Detection of Anti-nephrin Autoantibodies in Idiopathic Nephrotic Syndrome. — Journal of the American Society of Nephrology 2026

Listen at https://audioscholar.cc/episode/c4fw6sugta

Podden och tillhörande omslagsbild på den här sidan tillhör AudioScholar. Innehållet i podden är skapat av AudioScholar och inte av, eller tillsammans med, Poddtoppen.